Atara Biotherapeutics (ATRA) Short-term Investments (2014 - 2025)

Atara Biotherapeutics has reported Short-term Investments for 12 years, with the latest figure at $8.0 million in Q3 2025.

• For the quarter ending Q3 2025, Short-term Investments fell 61.56% year-over-year to $8.0 million; the trailing twelve-month figure through Sep 2025 stood at $8.0 million (down 61.56% YoY), and the FY2024 full-year result was $146000.0, down 99.44% from the prior year.
• Short-term Investments for Q3 2025 stood at $8.0 million, up from $146000.0 in the prior quarter.
• The five-year high for Short-term Investments was $265.0 million in Q4 2021, with the low at $146000.0 in Q1 2022.
• Historically, Short-term Investments has averaged $54.5 million across 5 years, with a median of $1.3 million in 2022.
• Annual changes were most pronounced in 2021 — Short-term Investments soared 128520.62% — and 2023, when it plunged 99.93%.
• Atara Biotherapeutics' Short-term Investments stood at $265.0 million in 2021, then tumbled by 43.44% to $149.9 million in 2022, then slumped by 82.73% to $25.9 million in 2023, then plunged by 99.44% to $146000.0 in 2024, then surged by 5358.9% to $8.0 million in 2025.
• The last three Short-term Investments figures came in at $8.0 million (Q3 2025), $146000.0 (Q4 2024), and $20.7 million (Q3 2024), per Business Quant data.